Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML - Results from Study AML-BFM 2004

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294960" target="_blank" >RIV/00216208:11130/15:10294960 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10294960

Výsledek na webu

<a href="http://dx.doi.org/10.1055/s-0035-1548816" target="_blank" >http://dx.doi.org/10.1055/s-0035-1548816</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1055/s-0035-1548816" target="_blank" >10.1055/s-0035-1548816</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML - Results from Study AML-BFM 2004

Popis výsledku v původním jazyce

Background: The outcome in children and adolescents with high-risk (HR) acute myeloid leukemia (AML) is still unsatisfactory. Therefore, in study AML-BFM 2004 we aimed to improve outcome of HR-patients by adding moderately dosed 2-Chloro-2-Deoxyadenosine(2-CDA) to the respective consolidation treatment backbone without increasing toxicity. The aim was to improve prognosis especially in FAB M4/M5/MLL patients, who represent the largest subgroup of HR patients. Patients and Methods: In total, 343 children and adolescents with HR-AML were randomized to receive or not 2-CDA (6 mg/m(2)/d, days 1, 3) in combination with cytarabine/idarubicine (AI = 500 mg/m(2) cytarabine 5 days continuous infusion plus 7 mg/m(2)/d idarubicin, days 3 and 5). Results: Resultsfor patients of the AI/2-CDA arm (n = 168) vs. the AI-arm (n = 175) were similar: 5-year overall survival 68 +/- 4 vs. 72 +/- 4 %, p(logrank) = 0.38, event-free survival 53 +/- 4 vs. 49 +/- 4 %, p(logrank) = 0.77; cumulative incidence of

Název v anglickém jazyce

Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML - Results from Study AML-BFM 2004

Popis výsledku anglicky

Background: The outcome in children and adolescents with high-risk (HR) acute myeloid leukemia (AML) is still unsatisfactory. Therefore, in study AML-BFM 2004 we aimed to improve outcome of HR-patients by adding moderately dosed 2-Chloro-2-Deoxyadenosine(2-CDA) to the respective consolidation treatment backbone without increasing toxicity. The aim was to improve prognosis especially in FAB M4/M5/MLL patients, who represent the largest subgroup of HR patients. Patients and Methods: In total, 343 children and adolescents with HR-AML were randomized to receive or not 2-CDA (6 mg/m(2)/d, days 1, 3) in combination with cytarabine/idarubicine (AI = 500 mg/m(2) cytarabine 5 days continuous infusion plus 7 mg/m(2)/d idarubicin, days 3 and 5). Results: Resultsfor patients of the AI/2-CDA arm (n = 168) vs. the AI-arm (n = 175) were similar: 5-year overall survival 68 +/- 4 vs. 72 +/- 4 %, p(logrank) = 0.38, event-free survival 53 +/- 4 vs. 49 +/- 4 %, p(logrank) = 0.77; cumulative incidence of

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Klinische Padiatrie

ISSN

0300-8630

e-ISSN

—

Svazek periodika

227

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

7

Strana od-do

116-122

Kód UT WoS článku

000354653100003

EID výsledku v databázi Scopus

2-s2.0-84929587307